2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112434
    PF-06733804 1873373-33-1 98%
    PF-06733804 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 8.4 nM, 6.2 nM and 2.2 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.
    PF-06733804
  • HY-112699
    AMPA receptor modulator-1 2036074-41-4 98%
    AMPA receptor modulator-1 is a potent, orally active and selective AMPAR regulatory protein TARP γ-8 negative modulator with a pIC50 of 9.7, more selective over GluA1/γ-2 (pIC50=5).
    AMPA receptor modulator-1
  • HY-112814
    VU6001376 1968546-34-0 98%
    VU6001376 is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4 PAM) with an EC50 of 50.1 nM.
    VU6001376
  • HY-115645
    R121919 hydrochloride 195055-66-4 98%
    R121919 (NBI30775) hydrochloride is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 hydrochloride has antidepressant and anxiolytic effects. R121919 hydrochloride alleviates defensive withdrawal in rats.
    R121919 hydrochloride
  • HY-115777
    ARN-6039 1675206-11-7 98%
    ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease.
    ARN-6039
  • HY-116808
    TPN729 936951-20-1 98%
    TPN729 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729 affects erectile function and it can be used for the research of erectile dysfunction.
    TPN729
  • HY-118098
    LY3202626 1628690-73-2 98%
    LY3202626 is a CNS penetrant BACE inhibitor with IC50s of 0.615 nM and 0.871 nM against BACE1 and BACE2, respectively.
    LY3202626
  • HY-119236
    CP-432 431990-08-8 98%
    CP-432 (CP-734432) is a EP4 receptor agonist with an IC50 of 2 nM for human sources, 8 nM for canine sources, and an EC50 of 1 nM for human sources. CP-432 stimulates cAMP production and activates β-lactamase (β-lactamase) activity via the cAMP response element signaling pathway. CP-432 is applicable to research related to glaucoma.
    CP-432
  • HY-119612
    XCT0135908 300837-31-4 98%
    XCT0135908 (XCT) is a selective Nurr1-RXRα activator with an EC50 value of 0.3 μM in human dopaminergic SH-SY5Y cells. XCT0135908 protects dopaminergic cells against the Parkinson’s disease-related toxin MPP+. XCT0135908 can be used for the research of Parkinson’s disease.
    XCT0135908
  • HY-119732
    KUNG94 2134571-29-0 98%
    KUNG94 is a selective Grp94/HSP90B inhibitor (IC50=8 nM). By inhibiting the chaperone function of Grp94, KUNG94 reduces the maturation and cell surface trafficking of its specific client proteins. KUNG94 can be used for studies on Grp94-related biological mechanisms, as well as diseases including cancer and primary open-angle glaucoma.
    KUNG94
  • HY-119941
    VU0652835 1848252-81-2 98%
    VU0652835 is a metabotropic glutamate receptor subtype 5 (mGlu5) negative allosteric modulator with an IC50 of 81 nM.
    VU0652835
  • HY-120408
    (±)-Scopolamine 138-12-5 98%
    (±)-Scopolamine (Atroscine) is the racemic modification of Scopolamine. (±)-Scopolamine inhibits α-adrenergic receptor activity. (±)-Scopolamine has Ki values of 33 μM and 7.25 nM for α1-adrenerg receptor and muscarinic cholinergic receptor, respectively.
    (±)-Scopolamine
  • HY-120681
    CGP39653 132472-31-2 98%
    CGP39653 is a competitive NMDA receptor antagonist that inhibits receptor function by competing with glutamate for the binding site.
    CGP39653
  • HY-122608
    Samelisant free base 1394808-82-2 98%
    Samelisant (SUVN-G3031) free base is a potent and selective histamine H3 receptor (H3R) inverse agonist with good brain penetration and oral bioavailability. Samelisant free base has a similar binding affinity towards human (hH3R; Ki=8.7 nM) and rat (rH3R;Ki=9.8 nM) H3R indicating no inter-species differences. Samelisant free base can be used for the research of sleep-related disorders.
    Samelisant free base
  • HY-12323G
    ISX-9 (GMP) 832115-62-5 98%
    ISX-9 (Isoxazole 9) is a potent inducer of adult neural stem cell differentiation.
    ISX-9 (GMP)
  • HY-123761
    L505-yne 1374647-07-0 98%
    L505-yne is an active site-directed γ-secretase inhibitor. L505-yne blocks photoaffinity labeling of PS1-NTF, PS1-CTF, and SPP by clickable GSI photoprobes, binds the γ-secretase complex and inhibits Aβ42 production. L458-BPyne can be used for the research of Alzheimer’s disease.
    L505-yne
  • HY-124244
    DB-959 1257641-15-8 98%
    DB-959 (PPARδ/γ agonist 1) is a potent PPAR agonist targeting PPARδ/γ. DB-959 improves spatial learning and memory in mice induced by Streptozotocin (HY-13753) and has the potential to improve Alzheimer's disease (AD)..
    DB-959
  • HY-125444
    TH251 1622059-04-4 98%
    TH251 is a LIMK1 and LIMK2 inhibitor with IC50s of 52 nM and 47 nM against LIMK1 and LIMK2, respectively. TH251 binds to inactive αC-out and DFG-out LIMK1 conformations, inhibits unphosphorylated LIMK1 and LIMK2 enzymatic activity, and exhibits unchanged potency despite PAK-mediated phosphorylation of either kinase. TH251 can be used for the research of cancers, glaucoma, and CNS diseases.
    TH251
  • HY-125790
    Cyclazocine 3572-80-3 98%
    Cyclazocine is a μ, δ, and κ opioid receptor modulator with Ki values of 0.32, 1.1, and 0.18 nM, respectively. Cyclazocine exhibits "mixed" pharmacological activities, acting as a μ-partial antagonist, κ-agonist, and low-affinity δ ligand. Cyclazocine shows antinociceptive activity in mice. Cyclazocine can be used in studies on psychoactive substance addiction.
    Cyclazocine
  • HY-12768B
    Sotuletinib dihydrochloride 2222138-40-9 98%
    Sotuletinib (BLZ945) dihydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib dihydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research.
    Sotuletinib dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity